-
Trastuzumab: dreams, desperation and hope Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-03-15 H. Michael Shepard
The story of trastuzumab begins with Axel Ullrich’s dedication to the concept that receptor tyrosine kinases must be the key to many human diseases. It continued with H. Michael Shepard’s dedication to making a cancer therapy that attacks tumour cells, not normal cells, and Dennis Slamon’s drive to save the lives of people with breast cancer. In this World View, H. Michael Shepard describes his personal
-
New pathogen on the block Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-03-11 Anna Dart
Fu et al. provide data indicating a pathogenic role for Streptococcus anginosus in gastric cancer.
-
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-03-07 Pascal Meier, Arnaud J. Legrand, Dieter Adam, John Silke
-
Catastrophic conformity Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-03-01 Gabrielle Brewer
Recently published in Nature, Fan et al. demonstrate that accumulation of advanced glycation end-products in the extracellular matrix of the liver increases viscoelasticity to promote hepatocellular carcinoma growth, independent of stiffness.
-
B-ring sterols to the rescue Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-03-01 Daniela Senft
Two independent studies published in Nature implicate distal cholesterol biosynthesis in the regulation of ferroptosis and show that 7-dehydrocholesterol (7-DHC) is an endogenous, anti-ferroptotic metabolite.
-
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-29 Edward W. Tate, Lior Soday, Ana Losada de la Lastra, Mei Wang, Hening Lin
-
Extrachromosomal DNA in cancer Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-26 Xiaowei Yan, Paul Mischel, Howard Chang
-
Black voices in cancer research and oncology Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-19 Kilan C. Ashad-Bishop, Onyinye D. Balogun, Runcie C. W. Chidebe, Leah M. Cook, Christina Towers
Over the past few years, there has been an increasing realization that we need a more equal, diverse and inclusive culture for truly successful cancer research to happen. Moreover, that research itself must be relevant to and engage a diverse patient population to achieve effective cancer care. Now is the time for action, so how do we attract and retain more diverse researchers to the cancer community
-
Fungi in cancer Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-12 Jessica Galloway-Peña, Iliyan D. Iliev, Florencia McAllister
Both the gut and the tumour microbiome are now established as crucial regulators of cancer phenotypes and have been implicated in cancer initiation, progression and therapy response. Although the role of bacteria in these processes is beginning to be unravelled, the relevance of fungi is only just emerging. In this Viewpoint, we asked experts to discuss the current knowledge on the mycobiome–cancer
-
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-12 Shaopeng Yuan, Jorge Almagro, Elaine Fuchs
-
Discovering new drivers of cancer aneuploidy Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-09 Juliann Shih
In this Tools of the Trade, Juliann Shih describes the development of BISCUT, which detects genomic loci that are subject to fitness advantages or disadvantages by interrogating the length distributions of partial somatic copy-number alterations to enable the discovery of new drivers of aneuploidy in cancer.
-
Cancer burden in low-income and middle-income countries Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-08 Sharmila Anandasabapathy, Chite Asirwa, Surbhi Grover, Chemtai Mungo
As cancer detection rates and therapy successes increase in high-income countries, it is predicted that over the next decade more than 75% of cancer-related deaths will occur in low-income and middle-income countries. Sub-Saharan Africa, which contains many of these countries, is currently unprepared with inadequate screening and detection methods, treatment and palliative care capacity. In this Viewpoint
-
Nanoreceptors take down mutant p53 Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-06 Gabrielle Brewer
Mutant gain-of-function p53 is commonly found in human cancers. Huang, Cao, Qian et al. developed and validated the use of multifunctional biomimetic nanoreceptors that bind to and promote the degradation of mutant p53 as a cancer therapy.
-
Inferring cancer metabolism from gene-expression data Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-05 Vakul Mohanty
In this Tools of the Trade article, Vakul Mohanty describes the development and use of METAFlux, a computational framework that infers metabolic flux from bulk and single-cell RNA-sequencing data.
-
Multiplex protein imaging in tumour biology Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-05 Natalie de Souza, Shan Zhao, Bernd Bodenmiller
-
Finding the needle in the haystack Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-02-02 Daniela Senft
Goddard et al. report that disseminated tumour cells evade T cell immunity due to their relative scarcity, which decreases the likelihood of T cell–tumour cell interactions.
-
Cholesterol-fuelled glioblastoma Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-01-31 Gabrielle Brewer
Zhao et al. identified lymphatic endothelial-like cells in glioblastoma and demonstrated their role in promoting tumour growth through increased glioblastoma cholesterol metabolism.
-
Differentiating high-grade neuroendocrine neoplasms Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-01-30 Rodrigo Gomes Taboada, Rachel P. Riechelmann
In this Journal Club, Taboada and Riechelmann discuss the importance of a study outlining a novel neuroendocrine neoplasm classification system.
-
Translating p53-based therapies for cancer into the clinic Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-01-29 Sylvain Peuget, Xiaolei Zhou, Galina Selivanova
-
Linking cell mechanical memory and cancer metastasis Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-01-18 Elena Cambria, Mark F. Coughlin, Marie A. Floryan, Giovanni S. Offeddu, Sarah E. Shelton, Roger D. Kamm
-
Epigenetic memory Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-01-15 Gabrielle Brewer
In a recent Developmental Cell paper, Falvo et al. establish a role for epigenetic memory of inflammatory injury in promoting pancreatic tumorigenesis.
-
Patient-derived organoids unveil sarcoma vulnerabilities Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-01-16 Tiago Góss dos Santos
In this Journal Club, Góss dos Santos discusses a study that successfully generated sarcoma-derived organoids and utilized them to identify a novel therapeutic target.
-
Towards targeting transposable elements for cancer therapy Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-01-16 Yonghao Liang, Xuan Qu, Nakul M. Shah, Ting Wang
-
Mapping the prostate cell family tree Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-01-10 Gabrielle Brewer
In this recent study, Giafaglione et al. uncover specific metabolic pathways that govern normal and malignant luminal prostate cell identity.
-
Sex affects cancer genomes Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-01-10 Daniela Senft
In a comprehensive study in acute myeloid leukaemia, Ozga et al. demonstrate sex-specific differences in the frequency and prognostic effect of genetic alterations.
-
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies Nat. Rev. Cancer (IF 78.5) Pub Date : 2024-01-09 Melody Riaud, Jennifer Maxwell, Isabel Soria-Bretones, Matthew Dankner, Meredith Li, April A. N. Rose
-
Decoding the basis of histological variation in human cancer Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-12-22 Masayuki Fujii, Shigeki Sekine, Toshiro Sato
-
Next-generation epidemiologic cohorts for cancer aetiology Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-12-15 Scarlett Lin Gomez, Iona Cheng
Epidemiologic cohorts of cancer aetiology have contributed substantially to the current understanding of cancer risk factors. Advancements in technologies could facilitate more precise, efficient and scalable assessments of emerging risk factors, ranging from ‘cells to society’. Because of the increasingly recognized necessity of addressing the roles of structural and social determinants of health
-
Approaching cancer during pregnancy Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-12-13 Leticia Varella, Ann H. Partridge
-
Spatial metabolic patterns Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-12-11 Anna Dart
Kreuzaler et al. examine the spatial metabolic rewiring driven by oncogenic MYC and show that it leads to increased import of vitamin B5, which represents a metabolic vulnerability to tumour progression.
-
Pressing defence Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-12-08 Daniela Senft
In this study, Bansaccal et al. analyse why, at some skin locations, oncogene-expressing cells rarely progress to cancer and found that a dense dermal collagen network prevents skin cancer formation.
-
How chemokines organize the tumour microenvironment Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-12-08 Thorsten R. Mempel, Julia K. Lill, Lukas M. Altenburger
-
Targeting cancer cell dormancy Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-12-07 Judith Agudo, Julio A. Aguirre-Ghiso, Mickie Bhatia, Lewis A. Chodosh, Ana Luísa Correia, Christoph A. Klein
The field of tumour dormancy, originally defined as a clinical phenomenon of late recurrence after a long, apparently disease-free period, has seen significant advances that now allow us to think about monitoring and targeting dormant tumour cells to prevent relapse. In this Viewpoint article, we asked experts to share their views on the steps that are needed to translate dormancy research into the
-
Fcγ receptors and immunomodulatory antibodies in cancer Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-12-07 Felipe Galvez-Cancino, Alexander P. Simpson, Cristobal Costoya, Ignacio Matos, Danwen Qian, Karl S. Peggs, Kevin Litchfield, Sergio A. Quezada
-
Removing barriers to address sex differences in anticancer drug toxicity Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-12-06 Berna C. Özdemir
-
The dynamic role of platelets in cancer progression and their therapeutic implications Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-12-01 Suping Li, Zefang Lu, Suying Wu, Tianjiao Chu, Bozhao Li, Feilong Qi, Yuliang Zhao, Guangjun Nie
-
Lighting up cancer initiation with mutant p53 reporters Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-11-30 Xiwen Tang
In this Tools of the Trade article, Xiwen Tang describes the development of in vivo reporters detecting mutant p53 at the protein level, which enables the visualization of precancerous cells during cancer initiation.
-
UXS1: a sweet spot for cell death Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-11-29 Gabrielle Brewer
Enzymes that produce metabolites specifically required by cancer cells have become attractive targets for therapy. Recently, Doshi et al. highlighted the potential of targeting the detoxifying enzyme UXS1 in cancer.
-
Eph receptors and ephrins in cancer progression Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-11-23 Elena B. Pasquale
-
Understanding and addressing race disparities in childhood cancer outcomes Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-11-20 M. Monica Gramatges
Vulnerable populations remain disproportionately at risk for inferior childhood cancer outcomes. Here, I outline the scope and magnitude of childhood cancer disparities worldwide and suggest multi-level clinical care and research opportunities to address cancer health inequities. Although childhood cancer survival rates have increased globally, there is a markedly inequitable distribution of these
-
Translating tumour immunity control Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-11-15 Glaucia N. M. Hajj
In this Journal Club, Hajj discusses a study demonstrating that oncogene activation modulates immune control through both transcription and translation.
-
Inflammatory neutrophils Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-11-09 Daniela Senft
Maas et al. identify an inflammatory, immunosuppressive phenotype in neutrophils that accumulates in brain malignancies, and show that this tumour-promoting neutrophil activation is driven by the brain tumour microenvironment.
-
Targeting the tumour’s little helpers Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-11-09 Linda Gummlich
Wang et al. show that antibiotic targeting of anaerobic intratumoral bacteria exposes a unique repertoire of microbial neoantigens that can successfully trigger cellular immunity against colorectal cancer in mice.
-
Deubiquitinases in cancer Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-11-07 Grant Dewson, Pieter J. A. Eichhorn, David Komander
-
Metabolic pathway analysis using stable isotopes in patients with cancer Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-10-31 Caroline R. Bartman, Brandon Faubert, Joshua D. Rabinowitz, Ralph J. DeBerardinis
-
How protons pave the way to aggressive cancers Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-10-26 Pawel Swietach, Ebbe Boedtkjer, Stine Falsig Pedersen
-
wildDISCO: HD whole-body imaging Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-10-23 Hongcheng Mai
In this Tools of the Trade article, Hongcheng Mai describes the development of wildDISCO, an approach for whole-body immunolabelling, optical clearing and imaging in mice.
-
The microbiome as a determinant of racial and ethnic cancer disparities Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-10-23 Doratha Byrd, Patricia Wolf
-
Advances in translational research of the rare cancer type adrenocortical carcinoma Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-10-19 Chandrayee Ghosh, Jiangnan Hu, Electron Kebebew
-
Breast milk for breast cancer detection Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-10-17 Gabrielle Brewer
Pregnancy-associated breast cancers are typically diagnosed at more advanced stages than other breast cancers. Recently, Saura et al. developed a non-invasive screening method using breast milk to diagnose patients prior to tumour detection by imaging.
-
Stem-like exhausted and memory CD8+ T cells in cancer Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-10-11 Thomas Gebhardt, Simone L. Park, Ian A. Parish
-
Transfer RNAs as dynamic and critical regulators of cancer progression Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-10-09 Alexandra M. Pinzaru, Sohail F. Tavazoie
-
Prime editing GEMMs to model cancer mutations Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-09-28 Nicolas Mathey-Andrews
In this Tool of the Trade article, Nicolas Mathey-Andrews describes the generation and use of a prime editor mouse that enables in vivo modelling of the multitude of cancer alleles found in human tumours.
-
Tertiary lymphoid structures as hubs of antitumour immunity Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-09-27 Gabriela Sarti Kinker, Tiago da Silva Medina
In this Journal Club, Kinker & Medina discuss a study showing the role of tumour-associated tertiary lymphoid structures in improving immunotherapy response and overall survival in patients with melanoma.
-
Computing brain metastasis impact Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-09-27 Daniela Senft
In a recent study, Sanchez-Aguilera, Masmudi-Martín et al. find that a molecular program explains the cognitive impairment often seen in patients with brain metastasis, challenging the prevailing paradigm of the tumour mass being the sole cause of altered brain function.
-
Enhanced transposable elements Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-09-27 Gabrielle Brewer
Karttunen et al. identify the contribution of transposable elements to gene regulatory function in colorectal and liver cancer cell lines.
-
Synaptic activity promotes melanoma formation Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-09-27 Daniela Senft
In a recent study, Tagore et al. find that the formation of synapse-like structures that serve to transfer GABA between premalignant melanocytes and keratinocytes promotes melanoma initiation by the BRAFV600E oncogene.
-
Harnessing the influenza virus to fight cancer Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-09-25 Dezhong Ji
In this Tools of the Trade article, Dezhong Ji describes the development and use of a chimeric antigenic peptide influenza virus (CAP-Flu) system as a cancer vaccine strategy to promote tumour-infiltrating T cell activation in lung metastasis.
-
Research does not happen in a socio-political vacuum — we should not pretend that it does Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-09-18 Eric K. Lau
On the basis of personal experiences and in light of current US socio-political realities, Eric Lau advocates for proactive actions against discrimination and emphasizes the need to speak out against oppression, urging research institutions to prioritize diversity, equity and inclusion.
-
Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters Nat. Rev. Cancer (IF 78.5) Pub Date : 2023-09-15 Andaleeb Sajid, Hadiar Rahman, Suresh V. Ambudkar